Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lemaitre Vascular (LMAT) Interest & Investment Income (2016 - 2025)

Lemaitre Vascular (LMAT) has disclosed Interest & Investment Income for 16 consecutive years, with $3.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Interest & Investment Income rose 107.89% to $3.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.1 million, a 164.58% increase, with the full-year FY2025 number at $13.1 million, up 164.58% from a year prior.
  • Interest & Investment Income was $3.3 million for Q4 2025 at Lemaitre Vascular, down from $3.9 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $3.9 million in Q3 2025 to a low of $1000.0 in Q1 2021.
  • A 5-year average of $1.1 million and a median of $758500.0 in 2023 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: tumbled 99.05% in 2021, then skyrocketed 16600.0% in 2022.
  • Lemaitre Vascular's Interest & Investment Income stood at $141000.0 in 2021, then soared by 217.02% to $447000.0 in 2022, then soared by 121.92% to $992000.0 in 2023, then surged by 62.3% to $1.6 million in 2024, then soared by 107.89% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for LMAT's Interest & Investment Income are $3.3 million (Q4 2025), $3.9 million (Q3 2025), and $3.0 million (Q2 2025).